Resilience Subsidiary Ology Bioservices Awarded Contract Worth Up To $250 Million from U.S. Department of Defense for Botulinum Neurotoxin Treatment

National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced the U.S. Department of Defense (DOD) has awarded UF startup Ology Bioservices, Inc. (Ology), a wholly-owned subsidiary of Resilience, a contract valued as much as $250 million for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT).

The U.S. Centers for Disease Control and Prevention classifies BoNT as a category ‘A’ threat – one that poses the highest risk to the public due to its extreme potency and lethality. Under the contract, Resilience’s Ology site in Alachua, Florida, will advance the MCM to U.S. Food and Drug Administration licensure, and then will manufacture the drug at a commercial scale and provide stock for military use.

Read more about Resilience Subsidiary Ology Bioservices Awarded Contract Worth Up To $250 Million from U.S. Department of Defense for Botulinum Neurotoxin Treatment.